Premium
XVI. CNS prophylaxis in aggressive lymphomas: for whom and how
Author(s) -
Benevolo Giulia,
Chiappella Annalisa,
Vitolo Umberto
Publication year - 2013
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2074
Subject(s) - medicine , lymphoma , chemotherapy , central nervous system , incidence (geometry) , aggressive lymphoma , diffuse large b cell lymphoma , complication , oncology , rituximab , physics , optics
Dissemination in the central nervous system (CNS) in patients with aggressive lymphoma is a relatively rare but a frequently deadly complication that occurs between 5 (diffuse large B-cell lymphoma, DLBCL) and 30% (Burk itt lymphoma, BL and B-cell lymphoblastic lymphoma, B-LL) [1] in different subtypes of non-Hodgkin lymphoma (NHL). However, although a CNS prophylaxis is normally included into treatment regimens for BL and B-LL, in other NHL a prophylactic treatment is not systematically warranted because it may increase the toxicity of systemic chemotherapy.